Navigation Links
Harvard Scientists Commend Erchonia for Excellence in Clinical Research for the Zerona Laser
Date:8/6/2013

McKinney, TX (PRWEB) August 06, 2013

In the latest volume of the medical journal, Lasers in Surgery and Medicine, three Harvard scientists reviewed the merits of laser therapy for body contouring and concluded that Erchonia’s research for its Zerona low-level laser device has, "set the precedent on how aesthetic devices should be evaluated." One of the article’s authors, Michael Hamblin, PhD., is recognized as the world’s leading expert in low level laser therapy, making the praise all the more significant.

Zerona was the first noninvasive aesthetic device to receive FDA market clearance in the U.S. for circumferential reduction of the waist, hips and thighs. Erchonia tested the Zerona laser using a placebo-controlled, randomized, double blind, multisite clinical investigation evaluating 67 study participants. The patients treated with the Zerona laser experienced an average reduction of 3.51 inches across the waist, hips and thighs in just two weeks.

The article praised Erchonia’s clinical approach for Zerona, noting, "The clinical trial absence of diet restrictions, exercise requirements or any other adjunctive components properly illustrated the clinical utility of the Zerona and set the precedent on how aesthetic devices should be evaluated."

Steven Shanks, president of Erchonia comments, "Having an expert such as Dr. Hamblin recognize the quality of our research and the clinical utility of Erchonia’s Zerona laser is truly an honor. For a small medical device manufacturer like Erchonia, quality clinical research is pivotal for our overall success. Erchonia’s research stands out in aesthetic medicine because more and more devices, such as Erchonia’s competitors, such as fat-freezing devices, are tested in non-randomized, non-controlled clinical trials."

This is not the first time an independent review recognized the clinical utility of Zerona. An article published in Clinics in Plastic Surgery in 2011 stated, "Zerona is in a unique and beneficial category as it exemplifies a truly non-invasive approach, inducing slimming without cell death or upregulation of inflammation."

For more information, please visit http://www.erchonia.com or http://www.myzerona.com.

About Erchonia

Erchonia is the global leader in low level laser healthcare applications. Over the last 15 years, Erchonia has been conducting research and development with the world’s leading physicians to advance the science of low level lasers. Prior to market introduction, all Erchonia lasers are proven safe and effective through independent clinical trials. Currently thousands of Erchonia’s lasers are used daily to reduce body fat, eliminate pain, and treat acne. For additional information, visit http://www.erchonia.com.

Read the full story at http://www.prweb.com/releases/2013/8/prweb10999754.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. How To Break the Sugar Habit, from the July 2013 Harvard Women's Health Watch
2. A Checklist for Heart Attack Prevention, from the July 2013 Harvard Men's Health Watch
3. Blueberries, Strawberries Protect the Heart, from the July 2013 Harvard Heart Letter
4. Nutrition in a Bottle: Sometimes More Hype Than Help, from the July 2013 Harvard Health Letter
5. Believing Myths and Misconceptions About Heart Disease May Increase Heart Attack Risk, from the June 2013 Harvard Heart Letter
6. Simple Steps for Boosting Energy, from the June 2013 Harvard Men's Health Watch
7. Joint surgery isn't the First Option for Knee and Hip Arthritis, from the June 2013 Harvard Health Letter
8. Science news from Harvard Stem Cell Institute
9. Bel Marra Health Reports on a New Harvard Study: Abuse of Prescription Drugs and Alcohol on the Steady Upswing
10. Diet Can Lower Blood Pressure As Much As Taking A Medication, From The March 2013 Harvard Men's Health Watch
11. Zinga! Frozen Yogurt Touts Harvard Study for National Nutrition Month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... , ... May 25, 2016 , ... ... Clearinghouse supporting the real time adjudication of medical service claims by Pharmacy Benefit ... their current medical claims management software. The TransactRx Cross Benefit Clearinghouse receives standard ...
(Date:5/25/2016)... ... May 25, 2016 , ... Conrad Siegel Actuaries, ... Medical and Prescription Drug survey , an employee benefits survey measuring ... conducted in December 2015, indicates that employers are turning to consumer directed health ...
(Date:5/25/2016)... ... 25, 2016 , ... America Walks , a national advocacy organization that ... University of Pittsburgh Graduate School of Public Health , has been awarded a ... other advocates from around the country to participate in a four-month training program designed ...
(Date:5/25/2016)... ... May 25, 2016 , ... Laser Skin & Wellness ... back the hands of time of female aging. The Juliet™ procedure ... with symptoms such as leakage, laxity, itchiness and pain have reported real relief from ...
(Date:5/25/2016)... Wayne, IN (PRWEB) , ... May 25, 2016 ... ... supplemental group health insurance, has seen a significant spike in their clients' employee ... in their annual biometric health screening by implementing a high-deductible health plan with ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... -- Cirujanos holandeses han puesto en marcha ... a compartir sus mejores prácticas por el mundo y ... de Europa, África, Asia y ... que combina la transmisión en vivo con mensajería instantánea ... Educación   "Imagine un médico de Medicines sans ...
(Date:5/24/2016)... May 24, 2016  Diana Russell suffers from a ... from the inside out.  This disease has put her ... her children and grandchildren to leave her home.  Because ... family cannot haul the wheelchair.  So if there is ... and Diana is left to wait for the bus. ...
(Date:5/24/2016)... May 24, 2016 Celsion Corporation (NASDAQ: ... company, today provided an update on its ongoing ... trial combining GEN-1, the Company,s DNA-based immunotherapy, with ... newly-diagnosed patients with advanced ovarian cancer who will ... GEN-1 is an IL-12 DNA plasmid vector formulated ...
Breaking Medicine Technology: